---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-25-024185"
form_type: "8-K"
ticker: "COLL"
cik: "0001267565"
company_name: "COLLEGIUM PHARMACEUTICAL, INC"
filed_at: "2025-03-17T23:59:59+00:00"
generated_at: "2026-05-24T15:16:17.181291+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Collegium nominates Carlos Paya; founder Heffernan retires as Chairman, Santini named; appoints David Dieter as GC

## Summary
- Dr. Carlos Paya nominated for election to Board at 2025 Annual Meeting; current venture partner at Abingworth/Carlyle.
- Founder and Chairman Michael Heffernan will not stand for re-election and retire from Board at Annual Meeting.
- Gino Santini named Chairman of the Board effective immediately after Annual Meeting; Heffernan to serve as Chairman until then.
- Director Gwen Melincoff also retiring from Board at Annual Meeting; departures part of board refreshment, not due to disagreements.
- David Dieter appointed EVP and General Counsel effective March 17, 2025; previously VP Legal at Horizon Therapeutics.

## SEC filing metadata
- accession: 0001104659-25-024185
- form_type: 8-K
- ticker: COLL
- cik: 0001267565
- company_name: COLLEGIUM PHARMACEUTICAL, INC
- filed_at: 2025-03-17T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 5.02, 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1267565/000110465925024185/0001104659-25-024185-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1267565/000110465925024185/tm259415d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-25-024185
- JSON: https://secwatch.observer/filing/0001104659-25-024185.json
- Plain text: https://secwatch.observer/filing/0001104659-25-024185.txt

## Key facts
- Executive change
  Carlos Paya was appointed as Director at COLLEGIUM PHARMACEUTICAL, INC.
  - Action: nominated
  - Role: Director
  source text: approved the nomination of Dr. Carlos Paya to stand for election
  evidence_url: https://www.sec.gov/Archives/edgar/data/1267565/000110465925024185/0001104659-25-024185-index.htm
- Executive change
  Gwen Melincoff departed as Director at COLLEGIUM PHARMACEUTICAL, INC.
  - Action: will not stand for re-election and retire
  - Role: Director
  source text: Gwen Melincoff also advised the Board that she will not stand for re-election at the Annual Meeting and will retire from the Board at that time.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1267565/000110465925024185/0001104659-25-024185-index.htm
- Executive change
  Michael Heffernan departed as Chairman of the Board at COLLEGIUM PHARMACEUTICAL, INC.
  - Action: will not stand for re-election and retire
  - Role: Chairman of the Board
  source text: Michael Heffernan, R.Ph., founder and current Chairman of the Board advised the Board that he will not stand for re-election at the Annual Meeting and will retire from the Board at that time.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1267565/000110465925024185/0001104659-25-024185-index.htm
- Executive change
  Gino Santini changed role as Chairman of the Board at COLLEGIUM PHARMACEUTICAL, INC.
  - Action: named Chairman of the Board
  - Role: Chairman of the Board
  source text: The Board has named Gino Santini, the Company’s lead independent director since 2018, as Chairman of the Board, effective immediately following the Company’s Annual Meeting.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1267565/000110465925024185/0001104659-25-024185-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.